Filing search / Context Therapeutics Inc. / "Audit"

8-K

EX-10.1

CNTX Context Therapeutics Inc.

23 Sep 24

Context to obtain exclusive development and commercialization rights to BA3362

7:33am

4.4 below), Context shall pay BioAtla non-refundable, non-creditable (save in the event of variance identified by audit in accordance with Section … extensions thereof), or for such longer period as may be required by Applicable Law. 4.7 Audit. At the request of BioAtla, Context shall, and shall cause its

8-K

EX-10.1

ly0xgwpz83g9q6wx81e

2 May 24

Context Therapeutics Announces $100 Million Private Placement

7:37am

8-K

EX-10.2

b9garnbs rg

2 May 24

Context Therapeutics Announces $100 Million Private Placement

7:37am

S-8

EX-23.1

765pijr 8sqk039qxy

21 Mar 24

Registration of securities for employees

8:28am